Search research articles
Contact Us
Filters
Showing results (291-300 of 311) with videos related to
Page
of 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
The Lancet. Oncology
|
October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Ahmad Awada, Agustin A Garcia, Stephen Chan, et al.
The Lancet. Haematology
|
February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
David A Sallman, Tessa Kerre, Violaine Havelange, et al.
Cancer Medicine
|
May 31, 2021
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
Nature Medicine
|
October 19, 2023
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
Diogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
Ian Krop, Vandana Abramson, Marco Colleoni, et al.
The Lancet. Oncology
|
June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Page
of 32
Search research articles
Search
Showing results (291-300 of 311) with videos related to
Sort By:
Page
of 32
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
The Lancet. Oncology
|
October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Ahmad Awada, Agustin A Garcia, Stephen Chan, et al.
The Lancet. Haematology
|
February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
David A Sallman, Tessa Kerre, Violaine Havelange, et al.
Cancer Medicine
|
May 31, 2021
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
Nature Medicine
|
October 19, 2023
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
Diogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
Ian Krop, Vandana Abramson, Marco Colleoni, et al.
The Lancet. Oncology
|
June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Page
of 32